New combo therapy targets hard-to-treat solid tumors
NCT ID NCT06781125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, JCXH-211, injected directly into tumors along with an anti-PD-1 antibody given through an IV. It is for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and tolerable for up to 72 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cancer drug TAK-505 enters first human trials
- New Dual-Target PET probe aims to sharpen cancer detection
- New hope for advanced cancer: experimental drug SHR-1681 enters human trials
- New drug cocktail aims to tackle Hard-to-Treat cancers
- New cancer drug SHR-4298 enters early human testing
- New MRI scan could sharpen cancer detection